Synergy Pharmaceuticals Inc (SGYP) 2.93 $SGYP
ContraVir Pharmaceuticals' CEO Issues Letter to Shareholders Highlighting Significant Progress
PR Newswire - Thu Dec 11, 9:10AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that its Chief Executive Officer James Sapirstein issued a letter to shareholders highlighting the significant progress the company has made toward its vision of becoming a leading developer of targeted antiviral therapies.
SGYP: 2.93 (-0.05)
Moventig cleared in Europe for OIC
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 6:14AM CST
SGYP: 2.93 (-0.05), PGNX: 7.10 (+0.16), CBST: 96.31 (+0.04), AZN: 71.80 (-1.80), SLXP: 103.36 (-2.79), NKTR: 15.31 (-0.29)
ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
PR Newswire - Tue Dec 09, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has initiated a pharmacokinetic (PK) study of FV-100, the Company's clinical-stage antiviral for treating shingles. The PK study, to be conducted at Duke University in early 2015, is designed to further understand the effect of a potent inhibitor of Cytochrome P450 3A4 on the pharmacokinetics of FV-100, allowing ContraVir to better understand the potential for clinically important drug-drug interactions and to further optimize treatment for Phase 3 development.
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals Drug Fares Well in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 20, 3:34PM CST
Synergy Pharmaceuticals (SGYP) announced positive top-line results from a phase II study on SP-333
SGYP: 2.93 (-0.05), ACT: 259.00 (-4.00), VRX: 138.71 (-0.18), IRWD: 15.00 (+0.09)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:14AM CST
SGYP: 2.93 (-0.05), ANV: 0.74 (-0.04), VIPS: 19.70 (-0.49), CLVS: 55.15 (+0.32), SUNE: 18.55 (-0.47), SNSS: 2.26 (unch), CLF: 6.74 (-0.20), GSAT: 2.58 (+0.05), EJ: 8.28 (-0.10), OPLK: 24.20 (+0.01), LITB: 6.05 (-0.22)
Synergy Pharmaceuticals Announces Positive Results of SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation
Business Wire - Wed Nov 19, 7:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from a phase 2 trial assessing safety, efficacy and dose-response of three different once-daily oral SP-333 tablets (1.0, 3.0 and 6.0 mg) compared with placebo in 289 patients with opioid-induced constipation (OIC). Preliminary analysis of the data indicates SP-333 met the study's primary endpoint and demonstrated statistically significant improvement in mean change from baseline in the number of spontaneous bowel movements (SBMs) during Week 4 of the treatment period. SP-333 was safe and well tolerated at all doses.
SGYP: 2.93 (-0.05)
Synergy Pharma posts 3Q loss
Automated Insights - Mon Nov 10, 5:01PM CST
NEW YORK (AP) _ Synergy Pharmaceuticals Inc. (SGYP) on Monday reported a loss of $23 million, or 24 cents per share, in its third quarter.
SGYP: 2.93 (-0.05)
Synergy Pharma beats by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:23PM CST
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals Reports Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 3:01PM CST
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), today reported its financial results and business update for the three and nine months ended September 30, 2014.
SGYP: 2.93 (-0.05)
Biotech Equities Scrutiny - Vanda Pharma, PDL BioPharma, Synergy Pharma, OPKO Health, and MiMedx
PR Newswire - Fri Nov 07, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), PDL BioPharma Inc. (NASDAQ: PDLI), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), OPKO Health Inc. (NYSE: OPK), and MiMedx Group Inc. (NASDAQ: MDXG). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, November 6, 2014, the NASDAQ Composite ended at 4,638.47, up 0.38%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,554.47, and the S&P 500 closed at 2,031.21, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 782.64, up 0.57%, with the index also advancing 11.74% in the previous three months. Register for your complimentary reports on these five stocks at:
SGYP: 2.93 (-0.05), OPK: 8.18 (-0.11), VNDA: 12.72 (-0.17), MDXG: 10.99 (-0.07), PDLI: 7.41 (-0.08)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 2.93 (-0.05), FURX: 104.77 (-1.41), SYN: 1.47 (-0.04), IRWD: 15.00 (+0.09), LXRX: 0.85 (-0.05), AZN: 71.80 (-1.80), TEVA: 55.92 (-0.92)
ContraVir Pharmaceuticals Selected to Present at Cavendish Global Health Impact Forum
PR Newswire - Wed Nov 05, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place November 10-13, 2014 at Oxford University in the UK. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
Business Wire - Wed Nov 05, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chairman and Chief Executive Officer, Dr. Gary S. Jacob, will present a corporate update at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 2:30 p.m. MST at The Biltmore Hotel in Phoenix, AZ.
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals Inc. Announces Issuance of $200 Million of 7.50% Convertible Senior Notes
Business Wire - Mon Nov 03, 3:01PM CST
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the closing of its previously announced private offering of $200 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019 (including the full exercise of the over-allotment option granted to the initial purchasers to purchase an additional $25 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019).
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals reports full exercise of additional USD25m convertible senior notes in over-allotment option
M2 - Fri Oct 31, 12:11PM CDT
Gastrointestinal company Synergy Pharmaceuticals (NasdaqGS:SGYP) disclosed on Thursday the initial purchasers' full exercise of over-allotment option to purchase another USD25m aggregate principal amount of 7.50% convertible senior notes due 2019.
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:11AM CDT
Synergy Pharmaceuticals, Inc. (SGYP) was a big mover last session, as the company saw its shares rise 10% on the day.
SGYP: 2.93 (-0.05), ADHD: 3.41 (+0.16), IG: 8.78 (+0.12), BIOD: 1.38 (-0.03)
Synergy Pharmaceuticals Inc. Announces Full Exercise of Over-Allotment Option
Business Wire - Thu Oct 30, 5:02AM CDT
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the full exercise of the over-allotment option granted to the initial purchasers to purchase an additional $25 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019 in connection with its previously announced $175 million Convertible Senior Note offering, bringing total gross proceeds from the offering to $200 million (before deducting the initial purchasers' discount and other offering expenses payable by the Company). The offering (including the over-allotment option) is expected to close on or about November 3, 2014, subject to customary closing conditions.
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals Inc. Announces Pricing of Private Offering of $175 Million of 7.50% Convertible Senior Notes
Business Wire - Wed Oct 29, 7:48AM CDT
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019. The Company also granted the initial purchasers of the notes an option to purchase, within a 13-day period beginning on and including the first date of the original issuance of the notes, up to an additional $25 million principal amount of notes, solely to cover over-allotments. The offering is expected to close on or about November 3, 2014, subject to customary closing conditions.
SGYP: 2.93 (-0.05)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:48PM CDT
SGYP: 2.93 (-0.05), ZLTQ: 29.06 (+0.32), IPHI: 14.53 (-0.07), REX: 58.45 (-0.26), AMCC: 5.87 (+0.03), INVN: 15.18 (-0.29), AKS: 5.20 (-0.13), X: 27.82 (-0.72), XOOM: 14.52 (-0.12), RFMD: 15.50 (-0.29)
Synergy Pharmaceuticals Inc. Announces Private Offering of Convertible Senior Notes
Business Wire - Tue Oct 28, 3:36PM CDT
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) (the "Company"
, a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that it is offering to sell up to $150 million principal amount of its convertible senior notes due 2019 (the "notes" through a private offering. The Company expects to grant the initial purchasers of the notes an option to purchase, within a 13-day period beginning on and including the first date of the original issuance of the notes, up to an additional $22.5 million principal amount of notes, solely to cover over-allotments.
SGYP: 2.93 (-0.05)
ContraVir Pharmaceuticals' CEO Issues Letter to Shareholders Highlighting Significant Progress
PR Newswire - Thu Dec 11, 9:10AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that its Chief Executive Officer James Sapirstein issued a letter to shareholders highlighting the significant progress the company has made toward its vision of becoming a leading developer of targeted antiviral therapies.
SGYP: 2.93 (-0.05)
Moventig cleared in Europe for OIC
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 6:14AM CST
SGYP: 2.93 (-0.05), PGNX: 7.10 (+0.16), CBST: 96.31 (+0.04), AZN: 71.80 (-1.80), SLXP: 103.36 (-2.79), NKTR: 15.31 (-0.29)
ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
PR Newswire - Tue Dec 09, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has initiated a pharmacokinetic (PK) study of FV-100, the Company's clinical-stage antiviral for treating shingles. The PK study, to be conducted at Duke University in early 2015, is designed to further understand the effect of a potent inhibitor of Cytochrome P450 3A4 on the pharmacokinetics of FV-100, allowing ContraVir to better understand the potential for clinically important drug-drug interactions and to further optimize treatment for Phase 3 development.
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals Drug Fares Well in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 20, 3:34PM CST
Synergy Pharmaceuticals (SGYP) announced positive top-line results from a phase II study on SP-333
SGYP: 2.93 (-0.05), ACT: 259.00 (-4.00), VRX: 138.71 (-0.18), IRWD: 15.00 (+0.09)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:14AM CST
SGYP: 2.93 (-0.05), ANV: 0.74 (-0.04), VIPS: 19.70 (-0.49), CLVS: 55.15 (+0.32), SUNE: 18.55 (-0.47), SNSS: 2.26 (unch), CLF: 6.74 (-0.20), GSAT: 2.58 (+0.05), EJ: 8.28 (-0.10), OPLK: 24.20 (+0.01), LITB: 6.05 (-0.22)
Synergy Pharmaceuticals Announces Positive Results of SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation
Business Wire - Wed Nov 19, 7:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from a phase 2 trial assessing safety, efficacy and dose-response of three different once-daily oral SP-333 tablets (1.0, 3.0 and 6.0 mg) compared with placebo in 289 patients with opioid-induced constipation (OIC). Preliminary analysis of the data indicates SP-333 met the study's primary endpoint and demonstrated statistically significant improvement in mean change from baseline in the number of spontaneous bowel movements (SBMs) during Week 4 of the treatment period. SP-333 was safe and well tolerated at all doses.
SGYP: 2.93 (-0.05)
Synergy Pharma posts 3Q loss
Automated Insights - Mon Nov 10, 5:01PM CST
NEW YORK (AP) _ Synergy Pharmaceuticals Inc. (SGYP) on Monday reported a loss of $23 million, or 24 cents per share, in its third quarter.
SGYP: 2.93 (-0.05)
Synergy Pharma beats by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:23PM CST
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals Reports Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 3:01PM CST
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), today reported its financial results and business update for the three and nine months ended September 30, 2014.
SGYP: 2.93 (-0.05)
Biotech Equities Scrutiny - Vanda Pharma, PDL BioPharma, Synergy Pharma, OPKO Health, and MiMedx
PR Newswire - Fri Nov 07, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), PDL BioPharma Inc. (NASDAQ: PDLI), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), OPKO Health Inc. (NYSE: OPK), and MiMedx Group Inc. (NASDAQ: MDXG). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, November 6, 2014, the NASDAQ Composite ended at 4,638.47, up 0.38%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,554.47, and the S&P 500 closed at 2,031.21, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 782.64, up 0.57%, with the index also advancing 11.74% in the previous three months. Register for your complimentary reports on these five stocks at:
SGYP: 2.93 (-0.05), OPK: 8.18 (-0.11), VNDA: 12.72 (-0.17), MDXG: 10.99 (-0.07), PDLI: 7.41 (-0.08)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 2.93 (-0.05), FURX: 104.77 (-1.41), SYN: 1.47 (-0.04), IRWD: 15.00 (+0.09), LXRX: 0.85 (-0.05), AZN: 71.80 (-1.80), TEVA: 55.92 (-0.92)
ContraVir Pharmaceuticals Selected to Present at Cavendish Global Health Impact Forum
PR Newswire - Wed Nov 05, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place November 10-13, 2014 at Oxford University in the UK. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
Business Wire - Wed Nov 05, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chairman and Chief Executive Officer, Dr. Gary S. Jacob, will present a corporate update at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 2:30 p.m. MST at The Biltmore Hotel in Phoenix, AZ.
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals Inc. Announces Issuance of $200 Million of 7.50% Convertible Senior Notes
Business Wire - Mon Nov 03, 3:01PM CST
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the closing of its previously announced private offering of $200 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019 (including the full exercise of the over-allotment option granted to the initial purchasers to purchase an additional $25 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019).
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals reports full exercise of additional USD25m convertible senior notes in over-allotment option
M2 - Fri Oct 31, 12:11PM CDT
Gastrointestinal company Synergy Pharmaceuticals (NasdaqGS:SGYP) disclosed on Thursday the initial purchasers' full exercise of over-allotment option to purchase another USD25m aggregate principal amount of 7.50% convertible senior notes due 2019.
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:11AM CDT
Synergy Pharmaceuticals, Inc. (SGYP) was a big mover last session, as the company saw its shares rise 10% on the day.
SGYP: 2.93 (-0.05), ADHD: 3.41 (+0.16), IG: 8.78 (+0.12), BIOD: 1.38 (-0.03)
Synergy Pharmaceuticals Inc. Announces Full Exercise of Over-Allotment Option
Business Wire - Thu Oct 30, 5:02AM CDT
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the full exercise of the over-allotment option granted to the initial purchasers to purchase an additional $25 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019 in connection with its previously announced $175 million Convertible Senior Note offering, bringing total gross proceeds from the offering to $200 million (before deducting the initial purchasers' discount and other offering expenses payable by the Company). The offering (including the over-allotment option) is expected to close on or about November 3, 2014, subject to customary closing conditions.
SGYP: 2.93 (-0.05)
Synergy Pharmaceuticals Inc. Announces Pricing of Private Offering of $175 Million of 7.50% Convertible Senior Notes
Business Wire - Wed Oct 29, 7:48AM CDT
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019. The Company also granted the initial purchasers of the notes an option to purchase, within a 13-day period beginning on and including the first date of the original issuance of the notes, up to an additional $25 million principal amount of notes, solely to cover over-allotments. The offering is expected to close on or about November 3, 2014, subject to customary closing conditions.
SGYP: 2.93 (-0.05)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:48PM CDT
SGYP: 2.93 (-0.05), ZLTQ: 29.06 (+0.32), IPHI: 14.53 (-0.07), REX: 58.45 (-0.26), AMCC: 5.87 (+0.03), INVN: 15.18 (-0.29), AKS: 5.20 (-0.13), X: 27.82 (-0.72), XOOM: 14.52 (-0.12), RFMD: 15.50 (-0.29)
Synergy Pharmaceuticals Inc. Announces Private Offering of Convertible Senior Notes
Business Wire - Tue Oct 28, 3:36PM CDT
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) (the "Company"
, a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that it is offering to sell up to $150 million principal amount of its convertible senior notes due 2019 (the "notes" through a private offering. The Company expects to grant the initial purchasers of the notes an option to purchase, within a 13-day period beginning on and including the first date of the original issuance of the notes, up to an additional $22.5 million principal amount of notes, solely to cover over-allotments. SGYP: 2.93 (-0.05)
